Research

Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial

Jon Pérez-Bárcena1,2, Juan A Llompart-Pou1, Javier Homar1, Josep M Abadal1, Joan M Raurich1, Guillem Frontera3, Marta Brell4, Javier Ibáñez4 and Jordi Ibáñez1

1Intensive Care Medicine Department, Son Dureta University Hospital, Andrea Doria 55, Palma de Mallorca, 07014, Spain
2Surgery Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, 08193, Spain
3Investigation Unit, Son Dureta University Hospital, Andrea Doria 55, Palma de Mallorca, 07014, Spain
4Neurosurgery Department, Son Dureta University Hospital, Andrea Doria 55, Palma de Mallorca, 07014, Spain

Corresponding author: Jon Pérez-Bárcena, jperez@hsd.es

Received: 1 Jul 2008 Revisions requested: 14 Jul 2008 Revisions received: 20 Aug 2008 Accepted: 29 Aug 2008 Published: 29 Aug 2008

Critical Care 2008, 12:R112 (doi:10.1186/cc6999)
This article is online at: http://ccforum.com/content/12/4/R112
© 2008 Pérez-Bárcena et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Experimental research has demonstrated that the level of neuroprotection conferred by the various barbiturates is not equal. Until now no controlled studies have been conducted to compare their effectiveness, even though the Brain Trauma Foundation Guidelines recommend that such studies be undertaken. The objectives of the present study were to assess the effectiveness of pentobarbital and thiopental in terms of controlling refractory intracranial hypertension in patients with severe traumatic brain injury, and to evaluate the adverse effects of treatment.

Methods This was a prospective, randomized, cohort study comparing two treatments: pentobarbital and thiopental. Patients who had suffered a severe traumatic brain injury (Glasgow Coma Scale score after resuscitation ≤ 8 points or neurological deterioration during the first week after trauma) and with refractory intracranial hypertension (intracranial pressure > 20 mmHg) first-tier measures, in accordance with the Brain Trauma Foundation Guidelines.

Results A total of 44 patients (22 in each group) were included over a 5-year period. There were no statistically significant differences in baseline characteristics, except for admission computed cranial tomography characteristics, using the Traumatic Coma Data Bank classification. Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group ($P = 0.03$). Under logistic regression analysis – undertaken in an effort to adjust for the cranial tomography characteristics, which were unfavourable for pentobarbital – thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; $P = 0.027$). There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.

Conclusions Thiopental appeared to be more effective than pentobarbital in controlling intracranial hypertension refractory to first-tier measures. These findings should be interpreted with caution because of the imbalance in cranial tomography characteristics and the different dosages employed in the two arms of the study. The incidence of adverse effects was similar in both groups.

Trial Registration (Trial registration: US Clinical Trials registry NCT00622570.)

Introduction

High dosages of barbiturates are used in patients with severe traumatic brain injury (TBI) who present with refractory intracranial hypertension (ICH) after medical and surgical treatment. This practice is recommended in the Brain Trauma Foundation (BTF) Guidelines, because this is the only second-level meas-

AUC: area under the curve; BTF: Brain Trauma Foundation; CI: confidence interval; ICH: intracranial hypertension; ICP: intracranial pressure; MAP: mean arterial pressure; SD: standard deviation; SOFA: Sepsis related Organ-Failure Assessment; TBI: traumatic brain injury.
ure for which there is class II evidence that it can reduce intracranial pressure (ICP) [1]. Nevertheless, its effect on outcome is unproven [2], mainly because of severe medical complications.

Within the family of barbiturates the oxibarbiturates and thio-barbiturates stand out, their primary representatives being pentobarbital and thiopental. Until now no controlled studies have been reported that compare the effectiveness of pentobarbital and thiopental in controlling ICH. At the experimental level, research has demonstrated that mechanisms of action and levels of neuroprotection differ between these agents [3-6]. For this reason, research is needed to compare the effectiveness of these two drugs in terms of controlling refractory ICH in patients with severe TBI.

Based on various studies conducted in laboratory animals [3-6], suggesting that the neuroprotective capacity of thiopental is superior, our working hypothesis was that thiopental is more effective than pentobarbital in controlling ICP in patients with severe TBI, with a similar incidence of adverse side effects. In support of our work in the present study, the BTF Guidelines recommend that studies be undertaken to compare the effectiveness of the different barbiturates that are currently used in TBI patients [1].

Materials and methods
We conducted a prospective, randomized cohort study comparing two treatments: pentobarbital and thiopental. Our primary objective was to compare the effectiveness of these agents in controlling refractory ICH in patients with severe TBI. Secondary objectives were to compare the incidence of secondary effects, especially arterial hypotension, which was defined as the presence of mean arterial pressure (MAP) under 80 mmHg at any point during barbiturate therapy.

This study was conducted at Son Dureta University Hospital (Palma de Mallorca, Spain) and was approved by the Ethics Committee of the Balearic Islands on 31 March 2002. It is registered with the US Clinical Trials Registry, with the number NCT00622570.

In all cases, the patient’s closest relative, legal representative, or guardian gave written informed consent for their inclusion in the study.

Inclusion criteria
Patients admitted to our intensive care unit (ICU) between May 2002 and July 2007 with a severe TBI (Glasgow Coma Scale [GCS] score after nonsurgical resuscitation ≤ 8) and presenting with refractory ICH (ICP > 20 mmHg), and who underwent first-level measures in accordance with the BTF Guidelines [7], were included. Refractory ICH was defined as follows: ICP 21 to 29 mmHg for 30 minutes or more, ICP of 30 to 39 mmHg for 15 minutes or more, or ICP greater than 40 mmHg for more than 1 minute, in the absence of external interventions. Included patients were required to be haemodynamically stable at the point of inclusion in the study; haemodynamic stability was defined as systolic blood pressure of 100 mmHg or greater.

Exclusion criteria
We did not include in the study patients who were younger than 15 or older than 76 years; patients with a GCS score of 3 upon admission and neurological signs of brain death (bilateral areactive midryasis and loss of brainstem reflexes); and patients who were pregnant, had barbiturate allergy or intolerance, or had a history of severe cardiac ventricular dysfunction with an ejection fraction under 35%.

General therapeutic protocol
All patients with severe TBI underwent cranial computed tomography (CT) upon admission and were categorized in accordance with the classification proposed by the Traumatic Coma Data Bank [8]. We also recorded findings of CTs conducted before inclusion of the patients in the study. The CT findings on inclusion were regarded to be the worst of the hospital stay; the prognostic value of such CT findings have been described by other authors [9]. CTs were independently reviewed and categorized by two neurosurgeons (JI and MB) who were unaware of the treatment group to which the patients had been assigned. In cases of disagreement between these investigators, a third investigator reviewed the CT images.

All patients’ ICP was monitored using an intraparenchymal Camino catheter (Integra Neurosciences, Plainsboro, NJ, USA). The ICP catheter was placed in the frontal region of the hemisphere with more radiological lesions on the CT. The systemic monitoring of these patients included invasive blood pressure, pulse oximetry, and a pulmonary artery thermodilution catheter. The ICP, MAP and cerebral perfusion pressure data were gathered on an hourly basis (one value every full hour) throughout the study using the Care Vue® clinical monitoring system (Phillips, Eindhoven, The Netherlands).

The general treatment objectives in patients with severe TBI were to maintain MAP above 80 mmHg, ICP below 20 mmHg, and cerebral perfusion pressure above 60 mmHg. To achieve these objectives, we used liquids and/or vasoactive support with norepinephrine (noradrenaline).

In patients with ICP greater than 20 mmHg, initial treatment included elevation of the head of the bed, keeping the neck straight, appropriate sedation, muscular paralysis, ventricular drainage (if the patient had visible ventricles on the CT), 20% mannitol (0.25 to 0.75 mg/kg), 7.5% hypertonic saline (2 ml/kg) and moderate hyperventilation (partial carbon dioxide tension of 30 to 35 mmHg). Neurosurgical interventions were undertaken when necessary to evacuate surgical lesions. This
approach can be considered conventional treatment and is included in the BTF Guidelines as first-tier therapy [7].

Patients whose ICP remained high with conventional treatment were included in the study. Before randomization of the patient to a study group, we required that patient to have received maximal medical treatment (first-level measures). In addition, we required a CT to have been conducted within 24 hours before inclusion of the patient in the study; intravenous administration of 0.7 g/kg mannitol 1 hour before randomization; or a plasmatic osmolarity measurement above 320 mOsm/kg, in order to ensure that hyperosmolar therapy had been optimized before inclusion.

Randomisation
Randomization was based on a computer-generated list that intercollated the two drugs. Allocation was done by the intensive care unit physician who was on duty, once the patient had been found to meet the inclusion criteria and none of the exclusion criteria. Data collection and patient follow up were conducted by the same investigator (JPB).

Blinding of treatment groups
The study was not blinded because it was difficult for us to mask treatment; thiopental is liophylized for administration and pentobarbital is not.

Administration of barbiturates and monitoring of effects
Pentobarbital was administered in accordance with the protocol established by Eisenberg and coworkers [10], using a loading dose of 10 mg/kg over 30 minutes followed by a continuous perfusion of 5 mg/kg per hour for 3 hours. This was followed by a maintenance dosage of 1 mg/kg per hour.

Thiopental was administered in the form of a 2 mg/kg bolus administered over 20 seconds. If the ICP was not lowered to below 20 mmHg, then the protocol permitted a second bolus of 3 mg/kg, which could be readministered at 5 mg/kg if necessary to reduce persistently elevated ICP. The maintenance dosage was an infusion of thiopental at a rate of 3 mg/kg per hour.

In both treatment groups, for cases in which the maintenance dosage did not achieve the reduction in ICP to below the 20 mmHg threshold, the maintenance dosage for both drugs could be increased by 1 mg/kg per hour, while looking for electroencephalographic burst suppression or even the flat pattern, in order to ensure that different doses of the two barbiturates were equipotent. Electroencephalography was conducted daily in a noncontinuous manner (Nicolet; Viasys Healthcare, Verona Road, Madison, WI, USA). Results were analyzed by an experienced neurologist who was blinded to the treatment of the patients.

In those patients in whom barbiturate coma did not control ICP, we used decompressive craniotomy and/or external lumbar drainage, in accordance with the Munch criteria, as lifesaving measures [11,12].

Effectiveness criteria
Adequate response to treatment was defined as a decrease in ICP to below 20 mmHg, and maintenance below this threshold for at least 48 hours. To describe the ICP, we also followed the criteria previously employed by Stocchetti and coworkers [13]; the arithmetic mean of ICP data recorded during every 24-hour period, after filtering to exclude inaccurate readings, was calculated and expressed as 'mean ICP'. Three ICP blocks were considered for further analysis: less than 20 mmHg, 20 to 30 mmHg, and more than 30 mmHg.

Uncontrollable ICP was defined as follows: ICP of 21 to 35 mmHg for 4 hours, ICP of 36 to 40 mmHg for 1 hour, or ICP above 41 mmHg for 5 minutes, in the absence of external interventions. We also defined as unresponsive to treatment those cases in which, because of refractory ICP, the patient needed some other treatment (surgery and/or lumbar drainage) and cases in which the patient progressed to brain death.

Although it was not a main objective of the study, patients were evaluated 6 months after injury using the Glasgow Outcome Scale [14].

Withdrawal of treatment
When ICP was controlled (<20 mmHg for 48 hours), we conducted a step-wise reduction in the barbiturate coma in steps that reduced the dosage by 50% every 24 hours until the infusion was suspended. In the event of ICP values rising to the study’s inclusion values during the withdrawal of barbiturate treatment, the perfusion dosage was once again increased to achieve control of the patient’s ICP.

Sample size
Accepting an α error of 0.05 and a β error of 0.2 in a bilateral hypothesis contrast, we estimated that 47 patients were needed in each group to detect differences of 30% or greater in the control of ICH. To calculate sample size, we assumed that the therapeutic response rate in the pentobarbital group would be 50%, excluding patients lost to follow up.

Statistical analysis
Quantitative variables are expressed as the mean and standard deviation from the mean (SD) in normal distributions, and as median and interquartile range in cases that were not normally distributed. Qualitative variables are expressed as percentages, along with 95% confidence interval (CI). To determine whether variables followed a normal distribution, we used the Shapiro Wilks test. For the comparison of quantitative variables, Student’s t-test was used if the variable followed a normal distribution. In other cases, we used the Mann-Whit-
ney U-test. For the comparison of qualitative variables, we used $\chi^2$ or Fisher’s exact test, as appropriate.

Given that the randomization did not create groups that were similar in terms of types of intracranial lesions shown on the CT results, which is a prognostic variable that influences the effectiveness of barbiturate treatment in controlling ICP, we conducted a multivariate analysis using binary logistic regression, so that we would include the prognostic variables with the most plausible association with the dependent variable ‘uncontrollable ICP’. These are variables such as age, GCS score at admission, and the worst CT obtained within 24 hours before inclusion of the patient in the study, as well as the type of barbiturate administered. To achieve this multivariate analysis, and given the small number of cases in each of the five groups in Marshall’s classification, the CT data were grouped into focal and diffuse lesions. We also included in the model the minimum daily MAP during barbiturate treatment, given that in the second and third days of treatment there were statistically significant differences between the groups in the univariate analysis. The significant variables identified by the ‘likelihood ratio’ $\leq 0.1$ test were used, along with those whose inclusion affected the calculation of the effect of the ‘treatment group’ variable.

Both treatment groups were very similar in terms of other known prognostic variables, such as the presence of hypoxia, hypotension before hospital admission and pupil reactivity, and the univariate analysis did not identify differences between them, so these were not included in the multivariate analysis.

To analyze the variable ICP, which was determined on a hourly basis, we calculated the area under the curve (AUC) at 24, 48 and 72 hours, and also standardized by time [15].

For all comparisons, we considered statistical significance to have been achieved if the two-tailed $\alpha$ error probability was 5% or less ($P \leq 0.05$). Statistical analyses were conducted using SPSS version 15 (SPSS Inc., Chicago, IL, USA).

**Results**

Preliminary results for the first 20 patients have already been published elsewhere [16].

From May 2002 to July 2007, 480 TBI patients were admitted to the intensive care unit of the Son Duretà University Hospital. Of these 480 patients, 71 (14.8%) presented with ICH refractory to first-level measures, of whom 44 were included in the study. The study was concluded prematurely because of the small number of cases in each of the five groups in Marshall’s classification, the CT data were grouped into focal and diffuse lesions. We also included in the model the minimum daily MAP during barbiturate treatment, given that in the second and third days of treatment there were statistically significant differences between the groups in the univariate analysis. The significant variables identified by the ‘likelihood ratio’ $\leq 0.1$ test were used, along with those whose inclusion affected the calculation of the effect of the ‘treatment group’ variable.

The summary of prognostic variables for the 44 patients is shown in Table 2. As in Table 1 the characteristics of the worst CT conducted before inclusion in the study differed between the two groups.

**Effectiveness criterion: control of intracranial pressure**

The distribution of the ICP during the first 3 days of treatment, according to Stocchetti’s criteria, is summarized in Table 3. The missing cases during these 3 days were due to brain death or to receipt of rescue treatment for uncontrollable ICP. Finally ICP was uncontrollable in 11 cases (50%) in the thiopental group and in 18 patients (82%) in the pentobarbital group ($P = 0.03$). In nonresponding patients, we chose to place a lumbar drainage in five, in three we opted for surgical treatment, and in three other patients we combined both treatments, drainage and surgery. Surgical decompression was conducted in four patients in the thiopental group and in two of the patients in the pentobarbital group. The number of hyperosmolar treatments administered (mannitol and/or hypertonic saline) during the barbiturate coma was similar in both groups: 16.5 (8.0 to 24.2) in the thiopental group and 16.5 (3.0 to 21.5) in the pentobarbital group ($P = 0.9$). The mean ± SD duration of the barbiturate coma was 156 ± 60 hours for thiopental and 108 ± 100 hours for pentobarbital ($P = 0.06$). Seven (31.8%) patients presented an ICP rebound with thiopental and six (27.3%) with pentobarbital ($P = 0.74$) during treatment withdrawal.

Figure 1 presents the AUC for ICP above 20 mmHg, standardized over time, as follows. The ICP value of AUC$_{0-24}$h was 458.00 mmHg-hour (95% CI = 421.84 to 494.16) in the thiopental group and 550.63 mmHg-hour (95% CI = 411.31 to 689.95) in the pentobarbital group. The AUC$_{0-48}$h was 913.18 mmHg-hour (95% CI = 814.08 to 1,012.27) in the thiopental group and 997.27 mmHg-hour (95% CI = 757.10 to 1,237.43) in the pentobarbital group. The AUC$_{0-72}$h in the thiopental group was 1,291.69 mmHg-hour (95% CI = 1,172.27 to 1,411.12) and 1,399.73 mmHg-hour (95% CI = 1,291.11 to 1,508.35) in the pentobarbital group. Standardized over time, the AUC per hour in the thiopental group was 23.90...
mmHg (95% CI = 22.00 to 25.81) and in the pentobarbital group it was 29.39 mmHg (95% CI = 23.20 to 35.59). Both treatment groups were similar in terms of known prognostic variables, such as presence of hypoxia, hypotension before hospital admission and pupil reactivity, and the univariate analysis did not identify differences between them. Therefore, these were not included in the multivariate analysis. The logistic regression analysis showed that, after adjusting for the worst CT and the type of barbiturate used, thiopental was five times less likely to be used compared with pentobarbital.

Table 1

Baseline characteristics of patient population

| Characteristic                          | Thiopental (n = 22) | Pentobarbital (n = 22) | P   |
|----------------------------------------|---------------------|------------------------|-----|
| Sex (male; n)                          | 19                  | 19                     | 1   |
| Age (years)                            | 26 (20 to 41)       | 32 (22 to 43)          | 0.45|
| ISS                                    | 25 (24 to 34)       | 25 (25 to 38)          | 0.77|
| SAPS II                                | 42 (28 to 54)       | 43 (38 to 46)          | 0.95|
| APACHE II                              | 23 (15 to 25)       | 20 (18 to 26)          | 0.27|
| APACHE III                             | 60 (38 to 73)       | 52 (32 to 76)          | 0.41|
| Associated lesion (n)                  |                     |                        |     |
| Thoracic injury                        | 7                   | 2                      | 0.13|
| Abdominal injury                       | 4                   | 1                      | 0.34|
| Extremities injury                     | 9                   | 5                      | 0.20|
| Admission CT (n)                       |                     |                        |     |
| Diffuse injury without brain swelling  | 12                  | 4                      | 0.046|
| Diffuse bilateral brain swelling       | 6                   | 12                     |     |
| Diffuse unilateral brain swelling with midline shift | 1 | 0 | |
| Any mass lesion > 25 ml                | 3                   | 6                      |     |

Age, ISS, SAPS II, APACHE II and APACHE III are expressed as median and interquartile range. APACHE, Acute Physiology and Chronic Health Evaluation; admission CT, admission computed tomography (according to the Traumatic Coma Data Bank); ISS, Injury Severity Score; SAPS, Simplified Acute Physiology.

Table 2

Prognostic variables of patient population

| Variable                               | Thiopental (n = 22) | Pentobarbital (n = 22) | P   |
|----------------------------------------|---------------------|------------------------|-----|
| Admission GCS score                    | 6.5 (3.0 to 7.2)    | 7 (4.7 to 10.0)        | 0.38|
| Out-of-hospital hypoxia (n)            | 5                   | 7                      | 0.63|
| Out-of-hospital hypotension (n)        | 5                   | 4                      | 1   |
| Pupillary reactivity (n)a              |                     |                        |     |
| One reacting                           | 3                   | 5                      | 0.66|
| Both reactingb                         | 12                  | 14                     |     |
| Pre-enrolment CT (n)                   |                     |                        |     |
| Diffuse injury without brain swelling  | 8                   | 5                      | 0.04|
| Diffuse bilateral brain swelling       | 1                   | 8                      |     |
| Diffuse injury unilateral brain swelling with midline shift | 5 | 1 | |
| Any mass lesion evacuated              | 7                   | 5                      |     |
| Nonevacuated mass lesion               | 1                   | 3                      |     |

Admission GCS is expressed as median (interquartile range). aPupillary reactivity at hospital admission. bMiotic pupils were considered as reactive. CT, computed tomography; GCS, Glasgow Coma Scale.
times more likely than pentobarbital to control ICP (odds ratio = 5.1, 95% CI = 1.2 to 21.9; \( P = 0.027 \)). The Hosmer-Lemeshow test indicated that the fit of the model was good (\( P = 0.799 \)). The association of focal lesions in the pre-inclusion CT with ICP control was 3.6 times higher than that for the diffuse lesions. The relative risk for good control of ICP in the thiopental versus pentobarbital group was 2.26 for patients with focal lesions and 3.52 for those who presented with diffuse lesions. The other variables analyzed did not exhibit a significant relationship to ICP control, and did not modify the effect of the barbiturate treatment, including the third day minimum MAP, which was significantly different between the two treatments (data not shown).

**Adverse side effects during the barbiturate coma**

The secondary effects during the barbiturate coma are presented in Table 4. In both groups almost all patients presented with at least one MAP measurement below 80 mmHg. There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment, or the maximum SOFA value \([17]\) during the entire period of barbiturate coma.

A thermol dilution catheter was placed in 42 patients to facilitate haemodynamic control. The haemodynamic changes produced during the barbiturate coma are presented in Table 5. Differences of note include the minimum MAP, the pulmonary wedge pressure value, and the maximum norepinephrine dosage on days 2 and 3.

**Six-month outcomes**

In the thiopental group, the neurological outcomes at 6 months (in accordance with Glasgow Outcome Scale score) were as follows: death in nine patients, vegetative state in two, severe disability in two, moderate disability in four and good recovery in four. In the pentobarbital group, the 6-month outcome was death in 16 patients, vegetative state in one, moderate disability in two and good recovery in two. In both groups one case was missing from the 6-month follow up analysis.

**Discussion**

The results of this study indicate that thiopental is five times more effective than pentobarbital in controlling refractory ICH. However, these findings must be interpreted with caution, given the small sample size and the fact that the study was unable to mask assignment to treatment groups.

**Differences between oxibarbiturates and thiobarbiturates**

The pharmacokinetic characteristics of thiopental and pentobarbital are different because their protein binding, distribution volume and clearance differ \([20]\). Nevertheless, the mean half life (thiopental 6 to 46 hours and pentobarbital 15 and 48 hours), which is the fundamental pharmacological parameter, differs little between the two agents. It therefore does not appear that these pharmacokinetic differences have clinical repercussions.

One difference between these two groups of barbiturates is the presence of active metabolites. Thiopental has five metabolites, of which four are inactive and one (pentobarbital, or pentobarbitone) is active. Therefore, pentobarbital is an active metabolite of thiopental. This fact, along with the great intra-individual and inter-individual variability in the metabolism of these agents (caused by the existence of enzymatic induction
phenomena associated with hepatic cytochrome P450), results in a weak correlation between serum concentrations and pharmacological effect. For this reason, monitoring this treatment with electroencephalography is strongly recommended.

At the experimental level, various studies have compared these two medications. Hatano and coworkers [21], in a study conducted in a dog model, concluded that thiobarbiturates provoke cerebral vasoconstriction, which could help to redistribute cerebral blood flow toward ischaemic zones. Cole and colleagues [4] demonstrated that thiopental reduced the size of the ischaemic area more than did pentobarbital, even though both drugs achieved electroencephalographic burst suppression patterns. Shibuta [5] observed that thiopental, but not pentobarbital, was capable of limiting the cytotoxic damage caused by nitric oxide. Almaas and coworkers [3] observed that the different barbiturates had different neuroprotective effects with respect to oxygen and glucose deprivation in a model using human neurone cultures. Thiopental exhibited a neuroprotective effect at all the dosages studied, whereas pentobarbital was neuroprotective only at elevated dosages. Finally, in an in vitro study, Smith and colleagues [6] demonstrated that although thiopental provoked 96% inhibition of lipid peroxidation, pentobarbital had almost no effect.

These experimental studies demonstrate that not all barbiturates are equal and that their neuroprotective capacity and effectiveness may differ [22]. Therefore, despite the unavoidable methodological limitations of the present study, we believe that our results may have clinical relevance.

**Secondary effects of barbiturate coma**

The most frequently detected secondary effect in our study, as might be expected, was arterial hypotension, which occurred in 21 patients in the thiopental group and 20 patients in the pentobarbital group. Although this incidence may be greater than that in previous studies [10], we attribute this to the definition of hypotension used (detection at any time in the barbiturate coma of MAP < 80 mmHg), which did not take the ‘time’ variable into account. For that reason, we collected data on other variables, such as maximum daily norepinephrine dosage and minimum daily MAP. Nearly all patients were monitored using a pulmonary artery thermodilution catheter, and arterial hypotension episodes were rigorously managed with fluid therapy and vasoactive drugs.

We would note that the changes produced by pentobarbital at the cardiac and respiratory level were, in general terms, greater than those produced by thiopental. This is because (as shown in Table 5) cardiac output, cardiac index, and partial oxygen tension/fraction of inspired oxygen ratio exhibited greater changes during treatment with pentobarbital than with thiopental. This observation contrasts with the findings of previous experimental studies [23], in which it appeared that at high doses pentobarbital was safer and better tolerated than thiopental.

Other complications (mostly infections) and the incidence of multiple organ dysfunction (identified using maximum SOFA) were similar in the two groups.

**Limitations of the study**

As previously noted, this study has two important limitations. First, it was not a blinded study because the pentobarbital was not liophylized and thiopental was. Second, the sample size was small, so that small changes in the principal variable studied, namely ICP control, could significantly affect the statistical analysis.
The classical view is that ICP response to barbiturates varies from 30% to 50%, and so it is possible that part of the difference found between drugs is due to poor response by the pentobarbital group as a result of any confounding bias. The randomization process is a potent mechanism that tends to eliminate bias by randomly distributing the values of all of the variables to the experimental groups. Nonetheless, the tool is not perfect and the groups frequently exhibit an imbalance in some confounding variable, especially when working with samples that are not very large. For this reason, in this study we used logistic regression analysis to eliminate any possible bias, and separate, independent analyses of the CT data were also conducted by two investigators who did not know the experimental group to which the patients belonged.

Another limitation is that the dosages in the two groups were not the same. This leaves the possibility that the reason for the difference between agents that we identified is inadequate pentobarbital dose. Although in the two groups barbiturates were used with the end-point of ICP control, in this type of patient we also employ daily noncontinuous electroencephalograhic monitoring. In this way, we believe that – despite dif-

| Table 5 | Systemic changes during barbiturate coma |
|---------|-----------------------------------------|
| Parameter | Pretreatment | 1st day | 2nd day | 3rd day | 4rd day |
| Cardiac output (l/minute)a | Thiopental | 6.8 ± 1.4 | 6.4 ± 1.5 | 6.0 ± 1.4 | 6.7 ± 1.5 | 6.6 ± 1.8 |
| | Pentobarbital | 7.4 ± 2.2 | 7.1 ± 1.9 | 6.5 ± 2.0 | 7 ± 1.4 | 6.1 ± 1.3 |
| Cardiac index (l/minute per m²) | Thiopental | 3.6 ± 0.6 | 3.4 ± 0.6 | 3.1 ± 0.6 | 3.6 ± 1.6 | 3.5 ± 0.9 |
| | Pentobarbital | 3.8 ± 1.2 | 3.8 ± 0.8 | 3.4 ± 0.8 | 3.6 ± 0.7 | 3.2 ± 0.6 |
| Peripheral venous resistance (dines/m²) | Thiopental | 1,015 ± 325 | 1,022 ± 347 | 1,140 ± 429 | 1,089 ± 289 | 1,029 ± 253 |
| | Pentobarbital | 952 ± 257 | 893 ± 210 | 1,003 ± 322 | 939 ± 261 | 914 ± 188 |
| Pulmonary artery wedge pressure (mmHg) | Thiopental | 10.4 ± 4.5 | 9.6 ± 3.6 | 10.1 ± 4.1* | 10.9 ± 4.6* | 11.4 ± 3.5* |
| | Pentobarbital | 11.6 ± 4.0 | 11.4 ± 3.1 | 12.8 ± 3.1 | 13.2 ± 2.1 | 13.9 ± 3.1 |
| mBP (mmHg)b | Thiopental | 92 ± 11 | 75 ± 7 | 76 ± 9* | 76 ± 6* | 76 ± 8 |
| | Pentobarbital | 94 ± 10 | 74 ± 1 | 68 ± 10 | 70 ± 1 | 70 ± 10 |
| NAD (μg/kg per minute)c | Thiopental | 0.18 ± 0.33 | 0.28 ± 0.27 | 0.37 ± 0.3* | 0.46 ± 0.39 | 0.56 ± 0.63 |
| | Pentobarbital | 0.19 ± 0.18 | 0.55 ± 0.68 | 0.73 ± 0.69 | 0.60 ± 0.44 | 0.96 ± 0.79 |
| PO₂/FiO₂d | Thiopental | 284 ± 130 | 300 ± 139 | 293 ± 132 | 285 ± 138 | 254 ± 119 |
| | Pentobarbital | 317 ± 127 | 304 ± 116 | 262 ± 125 | 211 ± 77 | 184 ± 92 |
| Haemoglobin | Thiopental | 10.9 ± 1.6 | 10.7 ± 1.3 | 11 ± 1.2 | 10.8 ± 0.9 | 10.7 ± 1.4 |
| | Pentobarbital | 10.6 ± 1.2 | 10.1 ± 1.0 | 10.4 ± 1.1 | 10.5 ± 1.1 | 10.2 ± 1.2 |
| Temperature (°C)e | Thiopental | 35.8 ± 0.5 | 34.6 ± 1.3 | 34.6 ± 3.4 | 34.9 ± 1.0 | 34.9 ± 1.0 |
| | Pentobarbital | 35.7 ± 1.0 | 34.6 ± 1.2 | 34.3 ± 1.3 | 34.4 ± 1.3 | 34.2 ± 1.1 |

aCardiac output, cardiac index, peripheral venous resistance and pulmonary artery wedge pressure: the values are the mean values over 24 hours. b mBP: minimum value of the medium blood pressure during the day. c NAD: maximum dose of Noradrenaline bitartrate during the day. d PO₂/FiO₂: ratio of partial oxygen tension to inspired fractional oxygen tension at 8:00 am. e Temperature: value of the minimum central temperature. *P < 0.05.
different doses – the effect of the two barbiturates can be considered as equipotent because we looked for burst suppression or even the flat electroencephalographic pattern if the ICP was not controlled and the patients remained haemodynamically stable.

Conclusion

In this patient sample, thiopental appeared to be more effective than pentobarbital in controlling ICH refractory to first-level measures, according to the BTF Guidelines. Nevertheless, these findings should be interpreted with caution because of the imbalance in CT characteristics and the different dosages employed in the two arms of the study. However, the present study is useful as a hypothesis testing exercise and will help to inform the design of future studies. These findings corroborate experimental evidence suggesting that there are differences in the neuroprotective mechanism between the two treatments, and this study may be a first step toward translating evidence from animal models to clinical disease.

The incidence of secondary effects during treatment was similar between groups.

Key messages

- High doses of barbiturates are used in those patients with severe TBI who present with refractory ICH, and this recommendation is included in the BTF Guidelines.
- Until now no controlled studies have been conducted to compare the effectiveness of pentobarbital and thiopental in controlling refractory ICH. Nevertheless, at the experimental level, research has demonstrated that their mechanisms and levels of neuroprotection differ.
- Thiopental appeared to be more effective than pentobarbital in controlling ICH refractory to first-tier measures, although these results should be interpreted with caution because of the imbalance in CT characteristics and other limitations of the study.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JPB was responsible for study design, acquisition of data, analysis and interpretation of data, and writing of the manuscript. JALP was responsible for acquisition of data and patient randomization. JH acquired data and conducted patient randomization. JMA conducted statistical analyses. GF conducted statistical analyses. MB was responsible for designing the study and reviewing CT findings. JI was responsible for designing the study and reviewing CT findings. JI revised the article critically and gave final approval to the version to be published.

Acknowledgements

This research was supported by a public grant from the Spanish government’s Fondo de Investigación Sanitaria (FIS PI020642), awarded to Dr J Pérez Bárcena. This public institution will not gain or lose financially from the publication of this manuscript in any way.

The preliminary results of the first 20 patients have already been published elsewhere [16].

References

1. The Brain Trauma Foundation: The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Anesthetics, analgesics, and sedatives. J Neurotrauma 2007, 24(suppl 1):S71-S76.
2. Roberts I: Barbiturates for acute traumatic brain injury. Cochrane Database Syst Rev 2000, 2:CD000339.
3. Aamodt R, Saugstad OD, Pleasure D, Rootwel T: Effect of barbiturates on hydroxyl radicals, lipid peroxidation, and hypoxic cell death in human NT2-N neurons. Anesthesiology 2000, 92:764-774.
4. Cole DJ, Cross LM, Drummond JC, Patel PM, Jacobsen WK: Thiopentone and methohexital, but not pentobarbitone, reduce early focal cerebral ischemic injury in rats. Can J Anaesth 2001, 48:807-814.
5. Shibuta S, Kosaka J, Mashimo T, Fukuda Y, Yoshiya I: Nitric oxide-induced cytotoxicity attenuation by thiopentone sodium but not pentobarbitone sodium in primary brain cultures. Br J Pharmacol 1998, 124:804-810.
6. Smith DS, Rehncrona S, Siesjo BK: Inhibitory effects of different barbiturates on lipid peroxidation in brain tissue in vitro: comparison with the effects of promethazine and chlorpromazine. Anesthesiology 1980, 53:186-194.
7. The Brain Trauma Foundation: The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Critical pathway for the treatment of established intracranial hypertension. J Neurotrauma 2000, 17:537-538.
8. Marshall LF, Marshall SB, Klauber MR, Van Berkum Clark M, Eisenberg H, Jane JA, Luerssen TG, Marmarou A, Foulkes MA: The diagnosis of head injury requires a classification based on computed axial tomography. J Neurotrauma 1992, 9:S287-S292.
9. Servadei F, Murray GD, Penny K, Teasdale GM, Dearden M, Ianotti F, Lapiere F, Maas AJ, Karimi A, Ohman J, Persson L, Stocchetti N, Trojanowsky T, Unterberg A: The value of the worst computed tomographic scan in clinical studies of moderate and severe head injury. European Injury Consortium. Neurosurgery 2000, 46:70-75.
10. Eisenberg HM, Frankowski RF, Contant CF, Marshal LF, Walker MD: High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 1998, 89:15-23.
11. Munch EC, Bauhuf C, Horn P, Roth HR, Schmiedek P, Vajkoczy P: Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage. Crit Care Med 2001, 29:76-79.
12. Abadal-Centelles JM, Llompart-Pou JA, Homar-Ramirez J, Pérez-Bárcena J, Rosselló-Ferrer A, Ibáñez-Juvec J: Neurologic outcome of postrumaffactory refractory intracranial hypertension treated with external lumbar drainage. J Trauma 2007, 62:282-286.
13. Stocchetti N, Zanaboni G, Colombo A, Citerio G, Beretta L, Ghisloni L, Zanier ER, Canavesi K: Refractory intracranial hypertension and second tier therapies in traumatic brain injury. Intensive Care Med 2008, 34:461-467.
14. Teasdale GM, Pettigrew LE, Wilson JT, Murray G, Jennett B: Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. J Neurotrauma 1998, 15:587-597.
15. Matthews JNS, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990, 300:230-235.
16. Pérez-Bárcena J, Barcelo B, Homar J, Abadal JM, Molina FJ, De la Peña A, Sahuquillo J, Ibáñez J: Comparison of the effectiveness of pentobarbital and thiopentol in patients with refractory

Available online http://ccforum.com/content/12/4/R112

(page number not for citation purposes)
intracranial hypertension. Preliminary report of 20 patients. Neurocirugia (Astur) 2005, 16:5-12.

17. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S: The use of SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective multicentre study. Intensive Care Med 1999, 25:686-698.

18. Ghajar J, Harini RJ, Narayan RK, Iacono LA, Firlik K, Patterson RH: Survey of critical care management of comatose, head-injured patients in the United States. Crit Care Med 1995, 23:560-567.

19. Jeevaratnam DR, Menon DK: Survey of intensive care of severely head injured patients in the United Kingdom. BMJ 1996, 312:944-947.

20. Steen PA, Michenfelder JD: Mechanisms of barbiturate protection. Anesthesiology 1980, 53:183-185.

21. Hatano Y, Nakamura K, Moriya S, Mori K, Toda N: The contractile responses of isolated dog cerebral and extracerebral arteries to oxybarbiturates and thiobarbiturates. Anesthesiology 1989, 71:80-86.

22. Drummond JC, Patel PM, Cole DJ: Cerebral protection: are all barbiturates created equal? Anesthesiology 1996, 85:1504-1505.

23. Roesch C, Haselby KA, Paradise RR, Krishna G, Dierdoff S, Wolfe TM, Rao CC: Comparison of cardiovascular effects of thiopental and pentobarbital at equivalent levels of CNS depression. Anesth Analg 1983, 62:49-53.